Medium dose of GC, the medium number of oral ulcers (OU), the Physician Global Assessment and the Patient Global Assessment at baseline and at the end of the follow-up period
ADA | IFX | Total | Test for mean | Test for median | ||||
Mean±SD | Median (25–75 percentile) | Mean±SD | Median (25–75 percentile) | Mean±SD | Median (25–75 percentile) | P value | P value | |
Medium dose of GC at baseline | 15.83±11.41 | 10 (7.5 to 25) | 13.41±11.69 | 10 (7.5 to 10) | 14.5±11.48 | 10 (7.5 to 20) | 0.514 | 0.333 |
Medium dose GC at the end of follow-up | 3.89±3.12 | 3.75 (2.5 to 5) | 3.86±5.51 | 2.5 (0 to 5) | 3.88±4.54 | 2.5 (0 to 5) | 0.986 | 0.449 |
Diff. medium dose of GC follow-up vs baseline | −11.94±12.38 | −7.5 (−22.5 to −2.5) | −9.55±12.95 | −6.88 (−10 to −2.5) | −10.63±12.6 | −7.5 (−16.25 to −2.5) | 0.556 | 0.652 |
Medium number of OU at baseline | 1.83±0.92 | 2 (1 to 2) | 1.73±0.7 | 2 (1 to 2) | 1.78±0.8 | 2 (1 to 2) | 0.682 | 0.872 |
Medium number of OU at the end of follow-up | 0.44±0.51 | 0 (0 to 1) | 0.55±0.67 | 0 (0 to 1) | 0.5±0.6 | 0 (0 to 1) | 0.602 | 0.757 |
Diff. medium number OU follow-up vs baseline | −1.39±0.7 | −1 (−2 to −1) | −1.18±0.66 | −1 (−1 to −1) | −1.28±0.68 | −1 (−1.5 to −1) | 0.344 | 0.39 |
Physician Global Assessment at baseline | 72.5±12.98 | 72.5 (65 to 80) | 73.18±17.08 | 80 (65 to 80) | 72.88±15.19 | 77.5 (65 to 80) | 0.89 | 0.647 |
Physician Global Assessment at the end of follow-up | 14.72±19.74 | 5 (0 to 20) | 19.05±17.65 | 10 (10 to 25) | 17.05±18.52 | 10 (0 to 25) | 0.475 | 0.213 |
Diff. Physician Global Assessment follow-up vs baseline | −57.78±24.27 | −60 (−75 to −40) | −52.86±30.89 | −60 (−70 to −40) | −55.13±27.78 | −60 (−75 to −40) | 0.588 | 0.702 |
Patient Global Assessment at baseline | 79.44±16.53 | 90 (70 to 90) | 80±14.47 | 80 (70 to 90) | 79.75±15.23 | 80 (70 to 90) | 0.91 | 0.901 |
Patient Global Assessment at the end of follow-up | 16.67±20 | 7.5 (0 to 30) | 19.32±16.64 | 20 (5 to 30) | 18.13±18.03 | 15 (0 to 30) | 0.65 | 0.355 |
Diff. Patient Global Assessment follow-up vs baseline | −62.78±27.98 | −65 (−85 to −55) | −60.68±26.65 | −65 (−75 to −50) | −61.63±26.92 | −65 (−82.5 to −50) | 0.81 | 712 |
ADA, adalimumab; GC, glucocorticoids; IFX, infliximab.